Therapeutic perspectives in hypertension: Novel means for reninangiotensinaldosterone system modulation and emerging device-based approaches

European Heart Journal

Volumn 32, Issue 22, 2011, Pages

  Unger, Thomas ^a   Paulis, Ludovit ^b,c   Sica, Domenic A ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Baroreflex; Controlled breathing; Endothelin; Fixed combinations; Renal denervation; Renalase; Reninangiotensinaldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; FADROZOLE; GUANFACINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KALLIKREIN; LCI 699; LOSARTAN; PMD 3117; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; BREAST; BREATHING EXERCISE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; DRUG TARGETING; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFLAMMATION; KIDNEY DENERVATION; LIBIDO DISORDER; MASTALGIA; MEDITATION; MENSTRUAL IRREGULARITY; MUSIC THERAPY; NATRIURESIS; NONHUMAN; PERIPHERAL EDEMA; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RETENTION; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VASODILATATION; VIRAL GENE DELIVERY SYSTEM; WATER RETENTION; YOGA;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ALDOSTERONE SYNTHASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; ENZYME INHIBITORS; GENE THERAPY; HUMANS; HYPERTENSION; MONOAMINE OXIDASE; PRESSORECEPTORS; PROTEASE INHIBITORS; RECEPTORS, CELL SURFACE; RECEPTORS, ENDOTHELIN; RENIN; RENIN-ANGIOTENSIN SYSTEM; RESPIRATORY THERAPY; SYMPATHECTOMY; VACCINES; YOGA;

EID: 81855199764     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr253     Document Type: Review

References (170)

1. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010;7:431-441.
2. Sica DA. Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? Curr Hypertens Rep 2008;10:415-420.
3. Krum H, Schlaich M, Sobotka P, Scheffers I, Kroon AA, de Leeuw PW. Novel procedure-and device-based strategies in the management of systemic hypertension. Eur Heart J 2011;32:537-544.
4. Schlaich MP, Krum H, Esler MD. New therapeutic approaches to resistant hypertension. Curr Hypertens Rep 2010;12:296-302.
5. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89:3A-9A.
6. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427. (Pubitemid 34596167)
7. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006;99:1355-1366. (Pubitemid 44949671)
8. Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med 2008;86:623-627.
9. Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T. Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res 2010;33:98-104.
10. Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997;10:306S-310S. (Pubitemid 28133254)
11. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci 1993;52:1461-1480.
12. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin1-9. Circ Res 2000;87:E1-E9.
13. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264:224-236.
14. Santos RA, Simoes E, Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the Gprotein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258-8263. (Pubitemid 36842532)
15. Lara Lda S, Cavalcante F, Axelband F, De Souza AM, Lopes AG, Caruso-Neves C. Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7). Biochem J 2006;395: 183-190.
16. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001;276:48623-48626.
17. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-1865.
18. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-A matter of love and hate. Peptides 2005;26:1401-1409. (Pubitemid 41021474)
19. Funke-Kaiser H, Reinemund J, Steckelings UM, Unger T. Adapter proteins and promoter regulation of the angiotensin II type 2 receptor-implications for cardiac pathophysiology. J Renin Angiotensin Aldosterone Syst 2010;11:7-17.
20. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-170.
21. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2006;11:1-6.
22. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlö f B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008;118:2523-2532.
23. Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlö f B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation acts antiinflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor {kappa}B. Hypertension 2010;55:924-931.
24. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, Greco L, Rosa M, Fauler B, Bader M, Alenina N, Guatimosim S. Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension 2008;52:542-548.
25. Fraga-Silva RA, Pinheiro SV, Gonçalves AC, Alenina N, Bader M, Santos RA. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Mol Med 2008;14:28-35. (Pubitemid 351356883)
26. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA, dos Santos RA, Simões e Silva AC, Teixeira MM. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 2010;185:5569-5576.
27. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RA. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 2010;56:112-120.
28. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlö f B, de Faire U, Mö rlin C, Karlberg BE, Wester PO, Björck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353: 611-616. (Pubitemid 29087980)
29. Hansson L, Lindholm LH, Ekbom T, Dahlö f B, Lanke J, Scherstén B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756.
30. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
31. Dahlö f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2000;359:95-1003.
32. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-2031. (Pubitemid 38781102)
33. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358: 1547-1559. (Pubitemid 351522739)
34. Kintscher U. ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. J Hypertens 2009;27:S36-S39.
35. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-207. (Pubitemid 46111014)
36. Kurtz TW. Beyond the classic angiotensin-receptor-blocker profile. Nat Clin Pract Cardiovasc Med 2008;5:S19-S26. (Pubitemid 351940520)
37. Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel M, Bähr IN, Hässle PL, Gust R, Fleck E, Unger T, Stawowy P, Kintscher U. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension 2009;54:738-743.
38. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009;32:826-834.
39. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-E8.
40. Gradman AH, Vivas Y. New drugs for hypertension: what do they offer? Curr Hypertens Rep 2006;8:425-432. (Pubitemid 44463728)
41. Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:163-175.
42. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009;119: 417-425.
43. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-599.
44. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial. J Hum Hypertens 2010;24:600-608.
45. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42: 1137-1143. (Pubitemid 37549068)
46. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-3078. (Pubitemid 27500110)
47. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20: 587-597. (Pubitemid 46678721)
48. Schefe JH, Neumann C, Goebel M, Danser J, Kirsch S, Gust R, Kintscher U, Unger T, Funke-Kaiser H. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens 2008;26: 1787-1794.
49. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113. (Pubitemid 43117745)
50. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008;19:743-748.
51. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004;114: 1128-1135. (Pubitemid 39578702)
52. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006;17:1950-1961. (Pubitemid 44036179)
53. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006;47:894-900. (Pubitemid 44297561)
54. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically spontaneously hypertensive rats on normal and high-salt diet. Am J Physiol Heart Circ Physiol 2008;295:H1117-H1121.
55. Seki Y, Ichihara A, Mizuguchi Y, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, Itoh H. Add-on blockade of (pro)renin receptor in imidapril-treated diabetic SHRsp. Front Biosci (Elite Ed) 2010;2:972-979.
56. Maschke U, Muller DN. The (pro)renin receptor and the mystic HRP-is there a role in cardiovascular disease? Front Biosci (Elite Ed) 2010;2:1250-1253.
57. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, Itoh H. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertens Res 2010;33: 177-180.
58. Danser AJ, Nguyen G. The renin academy summit: advancing the understanding of renin science. J Renin Angiotensin Aldosterone Syst 2008;9:119-123. (Pubitemid 351998221)
59. Nagai Y, Ichihara A, Nakano D, Kimura S, Pelisch N, Fujisawa Y, Hitomi H, Hosomi N, Kiyomoto H, Kohno M, Ito H, Nishiyama A. Possible contribution of the non-proteolytic activation of prorenin to the development of insulin resistance in fructose-fed rats. Exp Physiol 2009;94:1016-1023.
60. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Itoh H, Oike Y, Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007;48:422-429. (Pubitemid 47251433)
61. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009;58:1625-1633.
62. Nabi AH, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Prorenin has high affinity multiple binding sites for (pro)renin receptor. Biochim Biophys Acta 2009;1794:1838-1847.
63. Akunuri S, Christofi F, Wijetunge S, Hughes AD. Effects of prorenin-derived peptides on the proliferation of human cultured saphenous vein smooth muscle cells. In: Abstract Book of the 15th annual European Council for Cardiovascular Research meeting, La Colle sur Loup, France, 8-10.10.2010; p.41.
64. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010;327:459-463.
65. Dive V, Chang CF, Yiotakis A, Sturrock ED. Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? Curr Pharm Des 2009; 15:3606-3621.
66. Campbell DJ. Vasopeptidase inhibition: a double-edged sword? Hypertension 2003;41:383-389. (Pubitemid 36314604)
67. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998;11:363-372. (Pubitemid 28186749)
68. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000;35:1221-1225. (Pubitemid 30413654)
69. d'Uscio LV, Quaschning T, Burnett JC Jr, Lüscher TF. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. Hypertension 2001;37:28-33. (Pubitemid 32064235)
70. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111. (Pubitemid 38125125)
71. Norton GR, Woodiwiss AJ, Hartford C, Trifunovic B, Middlemost S, Lee A, Allen MJ. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12:563-571. (Pubitemid 29268387)
72. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Invest Drugs 2001;2: 1414-1422.
73. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat vs. Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2009;106:920-926.
74. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Bloodpressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
75. Birkenfeld AL, Adams F, Schroeder C, Engeli S, Jordan J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. Hypertension 2011;57:e4-e5.
76. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-930. (Pubitemid 37315491)
77. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15: 709-716. (Pubitemid 34804277)
78. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B, Patrick JL, Krause SL. Effects of eplerenone vs. losartan in patients with low-renin hypertension. Am Heart J 2005;150:426-433. (Pubitemid 41317608)
79. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-951.
80. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20:2641-2650.
81. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003;108: 1831-1838. (Pubitemid 37296092)
82. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
83. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321. (Pubitemid 36384098)
84. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007;25:891-894. (Pubitemid 46398886)
85. Chapman N, Dobson J, Wilson S, Dahlö f B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in patients with resistant hypertension. Hypertension 2007;49:839-845. (Pubitemid 351664214)
86. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003;16:80-86. (Pubitemid 36078597)
87. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 2010;24:532-537.
88. Karagiannis A, Tziomalos K, Papageorgiou A et al. Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother 2008;9:509-515. (Pubitemid 351425379)
89. Sica DA, Flack J. Treatment considerations with aldosterone receptor antagonists. J Clin Hypertens (Greenwich) 2011;13:65-69.
90. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005;10: 23-29. (Pubitemid 40895313)
91. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51:742-748. (Pubitemid 351301529)
92. Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, Collins JT, Blinn JR, Numann RE, Hu X, Huang HC. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010;53:4300-4304.
93. Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010;285: 29932-29940.
94. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005;111:3087-3094. (Pubitemid 40847786)
95. Huang BS, White RA, Jeng AY, Leenen FH. Role of central nervous system aldosterone synthase and mineralocorticoid receptors in salt-induced hypertension in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol 2009;296: R994-R1000.
96. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009;75: 936-944.
97. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010;56:831-838.
98. White WB, Calhoun DA, Krum H, Guo W, Trapani AJ, Lefkowitz M, Menard J. Blockade of aldosterone production as a novel approach to the management of high blood pressure: efficacy and tolerability of the aldosterone synthase inhibitor LC1699 in patients with Stage 1-2 hypertension. J Am Coll Cardiol 2010;55: E582.
99. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008;29:2171-2179.
100. Gamliel-Lazarovich A, Gantman A, Coleman R, Jeng AY, Kaplan M, Keidar S. FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice. J Hypertens 2010;28:1900-1907.
101. Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, Nakajima T, Horii M, Uemura S, Saito Y. Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006;47:133-138. (Pubitemid 44378236)
102. Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N. Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009;605:49-52.
103. Akizuki O, Inayoshi A, Kitayama T, Yao K, Shirakura S, Sasaki K, Kusaka H, Matsubara M. Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008;584: 424-434.
104. Kirkby NS, Hadoke PWF, Bagnall AJ, Webb DJ. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-1119. (Pubitemid 351415492)
105. Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007;28: 573-579. (Pubitemid 350026612)
106. Feldstein C, Romero C. Role of endothelins in hypertension. Am J Ther 2007;14: 147-153. (Pubitemid 46597652)
107. Weber MA, Black H, Bakris G, Krum H, Linas S,Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double blind, placebo-controlled trial. Lancet 2009;374:1423-1431.
108. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010;56: 824-830.
109. Webb DJ. DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 2010; 56:806-807.
110. Sica DA. Endothelin receptor antagonism: what does the future hold? Hypertension 2008;52:460-461.
111. Floyd DM, Sills MA. Pre-clinical development of PS433540, a dual-acting receptor antagonist (DARA) of the angiotensin and endothelin receptors. J Clin Hypertens (Greenwich) 2007;9:A158.
112. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir GV. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005;115:1275-1280. (Pubitemid 40629046)
113. Li G, Xu J,Wang P, Velazquez H, Li Y, Wu Y, Desir GV. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation 2008;117: 1277-1282. (Pubitemid 351365660)
114. Ghosh SS, Gehr TWB, Sica DA, Masilamani S, Ghosh S, Wang R, McGuire E, Quarrale AS. Effect of renalase inhibition on blood pressure. J Am Soc Nephrol 2006;17:208A.
115. Desir GV. Role of renalase in the regulation of blood pressure and the renal dopamine system. Opin Nephrol Hypertens 2011;20:31-36.
116. Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, Sampaio-Maia B, Quelhas-Santos J, Russell K, Russell R, Flavell RA, Pestana M, Giordano F, Desir GV. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int 2010; Dec 22 [Ahead of print].
117. Zhao Q, Fan Z, He J, Chen S, Li H, Zhang P, Wang L, Hu D, Huang J, Qiang B, Gu D. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med 2007;85:877-885. (Pubitemid 47077106)
118. Luft FC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab 2005;1:358-360. (Pubitemid 43960630)
119. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005;90:783-790. (Pubitemid 41406067)
120. Li H, Gao Y, Grobe JL, Raizada MK, Katovich MJ, Sumners C. Potentiation of the antihypertensive action of losartan by peripheral overexpression of the ANG II type 2 receptor. Am J Physiol Heart Circ Physiol 2007;292:H727-H735.
121. Alexander MY, Brosnan MJ, Hamilton CA, Downie P, Devlin AM, Dowell F, Martin W, Prentice HM, O'Brien T, Dominiczak AF. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc Res 1999;43:798-807. (Pubitemid 29369279)
122. Bledsoe G, Chao L, Chao J. Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2003;285:H1479-H1488. (Pubitemid 37169501)
123. Wang H, Katovich MJ, Gelband CH, Reaves PY, Phillips MI, Raizada MK. Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and longterm antihypertensive action by virally mediated delivery of ACE antisense cDNA. Circ Res 1999;85:614-622. (Pubitemid 29467850)
124. Phillips MI, Mohuczy-Dominiak D, Coffey M, Galli SM, Kimura B, Wu P, Zelles T. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense. Hypertension 1997;29:374-380. (Pubitemid 27074071)
125. Sun H, Zhang L, Wang A, Xue Z. Prolonged hypotensive effect of human tissue kallikrein gene delivery and recombinant enzyme administration in spontaneous hypertension rats. Exp Mol Med 2004;36:23-27. (Pubitemid 38374720)
126. Vanecková I, Kopkan L, Husková Z, Vanourková Z, Schejbalová S, Cervenka L, Kramer HJ. AT1 receptor antisense therapy transiently lowers blood pressure in Ren-2 transgenic rats. Vascul Pharmacol 2007;47:63-67. (Pubitemid 46818138)
127. Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 1998;31:1166-1170. (Pubitemid 28191513)
128. Landa MS, García SI, Schuman ML, Burgueño A, Alvarez AL, Saravia FE, Gemma C, Pirola CJ. Knocking down the diencephalic thyrotropin-releasing hormone precursor gene normalizes obesity-induced hypertension in the rat. Am J Physiol Endocrinol Metab 2007;292:E1388-E1394.
129. Kubo T, Ikezawa A, Kambe T, Hagiwara Y, Fukumori R. Renin antisense injected intraventricularly decreases blood pressure in spontaneously hypertensive rats. Brain Res Bull 2001;56:23-28. (Pubitemid 32962934)
130. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, Jennings GT, Bachmann MF. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007;25:63-72. (Pubitemid 44885665)
131. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Müller P, Jennings GT, Wagner F, Bachmann MF. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008;371: 821-827. (Pubitemid 351323893)
132. Cytos Biotechnology. Updates on the development of the hypertension vaccine CYT006-AngQb. http://www.cytos.com/userfiles/file/Cytos-Press-E-091110.
133. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004;107: 167-173. (Pubitemid 39070933)
134. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, Ménard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987; 84:4346-4350. (Pubitemid 17090931)
135. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, Carelli C, Galen FX, Menard J, Corvol P. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990;81:1899-1910. (Pubitemid 20183839)
136. Pramanik T, Sharma HO, Mishra S, Mishra A, Prajapati R, Singh S. Immediate effect of slow pace bhastrika pranayama on blood pressure and heart rate. J Alter Complement Med 2009;15:293-295.
137. Nidich SI, Rainforth MV, Haaga DA, Hagelin J, Salerno JW, Travis F, Tanner M, Gaylord-King C, Grosswald S, Schneider RH. A randomized controlled trial on effects of the Transcendental Meditation program on blood pressure, psychological distress, and coping in young adults. Am J Hypertens 2009;22: 1326-1331.
138. Oneda B, Ortega KC, Gusmão JL, Araújo TG, Mion D Jr. Sympathetic nerve activity is decreased during device-guided slow breathing. Hypertens Res 2010; 33:708-712.
139. Resperate for hypertension. Med Lett Drugs Ther 2007;49:55-56.
140. Resperate, http://www.resperate.com/MD (1 November 2010).
141. Parati G, Carretta R. Device-guided slow breathing as a non-pharmacological approach to antihypertensive treatment: efficacy, problems and perspectives. J Hypertens 2007;25:57-61. (Pubitemid 44885664)
142. Dibona GF, Esler MD. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010;298:R245-R253.
143. Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009;54:1195-1201.
144. Krum H, Sobotka P, Mahfoud F, Böhm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation 2011;123:209-215.
145. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-1281.
146. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
147. Doumas M, Douma S. Renal denervation: the jury is still out. Lancet 2010;376: 1878-1880.
148. Lohmeier TE. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001;14:147S-154S. (Pubitemid 32506709)
149. Lohmeier TE, Hildebrandt DA, Warren S, May PJ, Cunningham JT. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol 2005;288:R828-R836. (Pubitemid 40404155)
150. Schwartz SI, Griffith LS, Neistadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. Am J Surg 1967;114:5-15.
151. Sica DA, Lohmeier TE. Baroreflex activation for the treatment of hypertension: principles and practice. Expert Rev Med Devices 2006;3:595-601. (Pubitemid 44650449)
152. Ng MM, Sica DA, Frishman WH. Rheos: an implantable carotid sinus stimulation device for the non-pharmacologic treatment of resistant hypertension. Cardiol Rev 2011;19:52-57.
153. Scheffers IJ, Kroon AA, Tordoir JH, de Leeuw PW. Rheos baroreflex hypertension therapy system to treat resistant hypertension. Expert Rev Med Devices 2008; 5:33-39.
154. Illig KA, Levy M, Sanchez L, Trachiotis GD, Shanley C, Irwin E, Pertile T, Kieval R, Cody R. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006;44:1213-1218.
155. Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56:1254-1258.
156. Kroon A, Schnidli J, Scheffers I, Tordoir J, Mohaupt M, Allemann Y, Jordan J, Engeli S, Liebeskind U, Luft FC, Eckert S, Hansky B, Elletson M, de Leeuw P. Sustained blood pressure reduction by baroreflex activation therapy with a chronically implanted system: 4-year data of Rheos Debut-HT-Study in patients with resistant hypertension. J Hypertens 2010;28:E441.
157. Sica D, Bakris G, Bisognano J, Nadim M, Sanchez L for the Rheos Pivotal Trial Investigators. A phase III trial of baroreflex activation therapy for resistant hypertension: trial design and baseline characteristics in the Rheos Pivotal Trial. J Clin Hypertension 2010;12:A114.
158. Bakris G, Bisognano J, Nadim M, Sanchez L, Sica D, Schafer J for the Rheos Pivotal Trial Investigators. Potential of implantable carotid sinus stimulator for drug-resistant hypertension. In: 23rd Scientific Meeting of the International Society of Hypertension. Vancouver, Canada, September 2010.
159. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:443-462. (Pubitemid 34208333)
160. Milani RV. Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy. Am J Manag Care 2005;11: S220-S227. (Pubitemid 41361629)
161. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL. The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-1536.
162. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, Bunt AM. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-426. (Pubitemid 30312663)
163. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580. (Pubitemid 47028551)
164. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg vs. monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007;29:61-73. (Pubitemid 46414029)
165. US FDA. Drugs@FDA: FDA Approved Drug Products, http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search-Drug-Name &ms=y (15 February 2011).
166. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009;54:32-39.
167. Deeks ED. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs 2011;71:209-220.
168. Black HR. Triple fixed-dose combination therapy: back to the past. Hypertension 2009;54:19-22.
169. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010;32:1252-1269.
170. Simko F, Paulis L. Chronotherapy beyond blood pressure reduction? J Pineal Res 2008;45:227-228.